Rituximab, an anti-CD20 monoclonal antibody, represses Tfh differentiation by decreasing IL-21, which inhibits the differentiation of Tfh cells by distinct mechanisms and thus exert therapeutic effect on T1DM. The gene discussed is IL21; the disease is type 1 diabetes mellitus.